Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

PURPOSE The CD20 antigen is expressed on more than 90% of B-cell lymphomas. It is appealing for targeted therapy, because it does not shed or modulate. A chimeric monoclonal antibody more effectively mediates host effector functions and is itself less immunogenic than are murine antibodies. PATIENTS AND METHODS This was a multiinstitutional trial of the chimeric anti-CD20 antibody, IDEC-C2B8. Patients with relapsed low grade or follicular lymphoma received an outpatient treatment course of IDEC-C2B8 375 mg/m2 intravenously weekly for four doses. RESULTS From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13.0 months. Serum antibody levels were sustained longer after the fourth infusion than after the first, and were higher in responders and in patients with lower tumor burden. The majority of adverse events occurred during the first infusion and were grade 1 or 2; fever and chills were the most common events. Only 12% of patients had grade 3 and 3% grade 4 toxicities. A human antichimeric antibody was detected in only one patient. CONCLUSION The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy. Toxicity was mild. Attention needs to be paid to the rate of antibody infusion, with titration according to toxicity. Further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.

[1]  D. Maloney,et al.  IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma , 1997 .

[2]  W. Hiddemann,et al.  Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  D. Czerwinski,et al.  Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma , 1994 .

[4]  T. Tedder,et al.  CD20: a regulator of cell-cycle progression of B lymphocytes. , 1994, Immunology today.

[5]  J. Gribben,et al.  Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow , 1994 .

[6]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[7]  I. Bernstein,et al.  Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. , 1993, The New England journal of medicine.

[8]  T. Maughan,et al.  Adverse reactions to Campath-1H monoclonal antibody , 1993, The Lancet.

[9]  J. Armitage,et al.  Treatment of non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[10]  I. Bernstein,et al.  Monoclonal antibody-based therapies of leukemia and lymphoma. , 1992, Blood.

[11]  E. Everett,et al.  Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia , 1992, American journal of hematology.

[12]  S. Gillies,et al.  Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. , 1990, Journal of immunology.

[13]  J. Ghrayeb,et al.  Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Brown,et al.  Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. , 1988, The EMBO journal.

[15]  R. R. Robinson,et al.  Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. , 1987, Journal of immunology.

[16]  F. Appelbaum,et al.  Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.

[17]  T. Lister,et al.  Follicular lymphoma: prognostic factors for response and survival. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Carlo,et al.  Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. , 1984, Blood.

[19]  R. Dillman,et al.  Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Pinkus,et al.  Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. , 1984, Blood.

[21]  S. Sallan,et al.  Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. , 1981, Blood.

[22]  D. Kufe,et al.  Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. , 1980, Cancer research.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .